D
25.25
0.00 (0.00%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Denali Therapeutics Inc. | Bearish | Bearish |
Stockmoo Score
-0.4
|
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Crestline Management, Lp | 30 Jun 2024 | 4,760,732 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (HC Wainwright & Co., 256.44%) | Buy |
| Median | 30.50 (20.79%) | |
| Low | 26.00 (Wedbush, 2.97%) | Buy |
| Average | 40.17 (59.09%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 23.55 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 09 Sep 2024 | 35.00 (38.61%) | Buy | 25.59 |
| B of A Securities | 04 Sep 2024 | 29.00 (14.85%) | Buy | 25.16 |
| HC Wainwright & Co. | 04 Sep 2024 | 90.00 (256.44%) | Buy | 25.16 |
| 15 Aug 2024 | 90.00 (256.44%) | Buy | 23.67 | |
| Citigroup | 02 Aug 2024 | 32.00 (26.73%) | Buy | 21.87 |
| Wedbush | 02 Aug 2024 | 26.00 (2.97%) | Buy | 21.87 |
| JP Morgan | 10 Jul 2024 | 29.00 (14.85%) | Buy | 21.65 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |